The deal is highly likely to close given insider support (41% committed) and simple majority vote threshold. The $100M cash consideration (~$6.68/share) represents a significant premium to the ~$3.75 pre-announcement price. Post-closing, Cumberland becomes a development-stage biotech with ifetroban pipeline — a binary-risk profile. Traders should monitor the June 24 vote; any delay or shareholder opposition would be a negative surprise. The retained ifetroban DMD program has Fast Track designation and positive Phase 2 data, providing optionality.
Price Chart
Executive Summary
Cumberland Pharmaceuticals is seeking shareholder approval to sell its FDA-approved commercial product portfolio (Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ, and Talicia equity interests) to an affiliate of Apotex Inc. for $100 million in cash at closing. The company will retain its ifetroban clinical-stage pipeline and CET subsidiary. The board unanimously recommends approval, and insiders holding ~41% of shares have already committed to vote in favor via support agreements. The special meeting is scheduled for June 24, 2026.
Key Financial Metrics
Key Facts
- Apotex will pay $100 million in cash at closing for Cumberland's FDA-approved commercial product assets and Talicia equity interests.
- Cumberland retains its ifetroban product candidates (DMD, SSc, IPF programs) and CET subsidiary.
- Insiders holding ~41% of outstanding shares have signed voting and support agreements to vote in favor.
- Board of directors unanimously recommends approval; VelocityHealth Securities issued fairness opinion.
- No appraisal rights for shareholders under Tennessee law.
- Simple majority of outstanding shares (7,491,554 of 14,983,107) required for approval; abstentions and broker non-votes count as votes against.
- Termination fee of $4 million payable by Cumberland under certain conditions (e.g., superior proposal, board recommendation change).
- Apotex has agreed to pay up to $10 million in milestone payments related to Vibativ government contract and net sales.
- Pro forma balance sheet shows estimated gain on sale of ~$63 million after transaction costs and taxes.
- Special meeting scheduled for June 24, 2026; expected closing in Q2 or Q3 2026.
Financial Impact
$100 million cash consideration at closing, representing ~$6.68 per share based on 14.96M shares outstanding, with an additional up to $10 million in Vibativ milestones. Pro forma net cash position of ~$110 million post-closing.
Risk Factors
- Shareholder vote failure — though unlikely given 41% insider support, broker non-votes count as 'against'.
- Regulatory or third-party consent delays could push closing past the August 20, 2026 outside date.
- Post-closing, Cumberland becomes a pure-play development-stage company with no commercial revenue — high execution risk on ifetroban pipeline.
- Litigation risk from shareholders challenging the deal or seeking appraisal (though no appraisal rights exist).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFM14A Filing (Primary) | 0001104659-26-065876 |
| Document: tm2612585-2_defm14a.htm | 0001104659-26-065876 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $5.22 | awaiting T+1 | — | $4.35 (−16.67%) |
Oct 23, 2026 3d ago | 8-K | $8.46 | awaiting T+1 | — | $4.35 (−48.58%) |
Aug 28, 2026 8w ago | 8-K | $6.69 $6.56 | ▲ +1.94% | ▲ +1.26% | $4.35 (+34.98%) |
Jul 13, 2026 15w ago | Press Release | $6.54 $6.99 | ▲ +6.80% | ▲ +6.45% | $4.35 (−33.49%) |
May 26, 2026 21w ago | DEFM14A | $5.77 $5.86 | ▲ +1.56% | ▲ +1.55% | $4.35 (−24.61%) |
Apr 23, 2026 26w ago | DEFA14A / 8-K | $3.90 $4.06 | ▲ +4.10% | ▲ +3.32% | $4.35 (+11.54%) |
Mar 9, 2026 33w ago | DEFA14A | $3.16 $3.08 | ▼ −2.53% | ▼ −2.43% | $4.35 (+37.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers